Helus Pharma CEO to join TD Cowen neuropsychiatry summit fireside chat

Helus Pharma, the commercial operating name of Cybin Inc., announced on September 21, 2026 that Chief Executive Officer Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually on September 23, 2026.¹ The fireside chat will be webcast live on Wednesday, September 23, 2026 at 9:00 a.m. EDT.¹ Investors can register for the webcast, and a replay will be made available on the Events & Presentations page of Helus Pharma's investor relations website.¹

The release does not specify the topics to be covered in the fireside chat.

Helus Pharma describes itself as the commercial operating name of Cybin Inc., a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity.¹ According to the release, Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA, in Phase 2 for generalized anxiety disorder.¹ The company also said it has an extensive research portfolio of investigational NSAs.¹

The filing notes that the company operates in Canada, the United States, the United Kingdom, and Ireland.¹ The release also cautions that the U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the company, and the efficacy of such products has not been confirmed by approved research.¹